Jupiter Neurosciences, Inc. announced the publication in the Journal of Alzheimer's Disease of "JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model." This research, performed in collaboration with the University of Miami Miller School of Medicine demonstrated that a novel, oral formulation of resveratrol, JOTROL, was able to deliver therapeutically viable levels of resveratrol in a disease mouse model of Alzheimer's disease (AD). The results showed that JOTROL significantly increased bioavailability over non-formulated resveratrol and that treatment resulted in AD-related gene expression changes, as well as changes in inflammatory gene and cytokine levels. JOTROL may be effective as a prophylaxis and/or treatment for AD through increased expression and/or activation of neuroprotective genes, suppression of pro-inflammatory genes, and regulation of central and peripheral cytokine levels.
Jupiter Neurosciences, Inc.
Equities
JUNS
US48208B2034
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+43.00% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |